MS STUDY DAY 2014: AN OVERVIEW
Who was the event aimed at?
The study day was aimed at people newly diagnosed with MS, interested in therapies or currently on therapies.

When did it happen?
The event was held on Friday, 26th September 2014… at Twickenham Stadium.

I was unable to attend, can I still view the content?
If you were unable to attend, the event was recorded. You can view a selection of talks by clicking on the video links here.

Source MS Society:
Published date: 27 Nov 2014 at 1:01PM

From today Tecfidera, a treatment for relapsing remitting MS, will be made available on the NHS in England and Wales; it is already available in Northern Ireland and Scotland. Read on.

Source MS Society:
A major independent review was published yesterday on the Work Capability Assessment – the test designed and used by the Department of Work and Pensions (DWP) to determine the entitlement of disabled welfare claimants to Employment and Support Allowance (ESA). Read on.

Fingolimod (Gilenya) not effective in primary progressive MS
Source MS Society:
“Note – While these results are disappointing, they do not affect the proven effectiveness of Gilenya in relapsing remitting MS.”
Novartis – the pharmaceutical company that manufacture Gilenya – carried out a global phase 3 clinical trial involving 940 people with primary progressive MS, known as INFORMS. The trial aimed to evaluate the effect of Gilenya (in the form of a once daily tablet) on delaying the progression of disability compared to a dummy drug.
Novartis have announced that results from this trial indicate that Gilenya is not an effective treatment for primary progressive MS. The full results will be presented at an upcoming scientific conference. Read on.

Source BBC:
Work to build a £44m brain imaging centre to help experts better understand the causes of conditions like dementia and multiple sclerosis has begun in Cardiff.
Researchers at the Cardiff University site will use mapping techniques to get a more detailed look at how the brain works. Read on.

Source MS Society:
Published date: 30 Oct 2014 at 1:23PM
The disability benefit Employment and Support Allowance (ESA) has featured heavily in the news in the last 24 hours.
While the BBC has reported leaked documents about the future of payments, a major announcement on the new company replacing the assessment provider Atos has also been made. Read on.

Source MS Society:
We are delighted to announce funding for 15 exciting new research projects, costing a total of £1.45 million.

This brings our current number of active projects to 59, with research spanning cause, cure, symptom relief and MS services. Read on.

Source: MS Trust
A report published today by the MS Trust finds that 30,000 people with MS live in areas where their specialist nurses are managing twice the sustainable level. This may mean that these people are not receiving all the support that they need. Read on